Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Reactogenicity, and Immunogenicity of an Mpox mRNA Vaccine Candidate, BNT166a, in Healthy Participants Aged 18 Years and Older in African Countries: A Randomized, Double-blind, Placebo-controlled Phase II Trial

NCT07379580 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT07379580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07379580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Reactogenicity, and Immunogenicity of an Mpox mRNA Vaccine Candidate, BNT166a, in Healthy Participants Aged 18 Years and Older in African Countries: A Randomized, Double-blind, Placebo-controlled Phase II Trial
Lead sponsor
BioNTech SE
Phase
Phase 2
Overall status
Recruiting
Start date
February 20, 2026
Completion date
June 30, 2027
Enrollment
310 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

mpox (monkeypox), orthopoxvirus infection, smallpox